Investors this morning will find out more about the fate of Aeterna Zentaris Inc.'s new drug application (NDA) for Macrilen (macimorelin), an oral ghrelin agonist for use as a diagnostic in evaluating adult growth hormone deficiency (AGHD) in the wake of a complete response letter (CRL) from U.S. regulators.